Breast cancer (BC) is the most common and leading cause of cancer deaths in women. Despite the improved outcomes which have been achieved by earlier detection and recent advances in therapy, recurrence still occurs in over 20% of patients ([@bib8]; [@bib7]; [@bib11]). It is therefore becoming increasingly important to identify biomarkers that can aid in assessing a patient\'s risk and response to therapy and which might also act as novel targets for immunotherapies ([@bib14]; [@bib13]). Although identifying tumour-associated antigens that induce adaptive Tcell immunity is a prerequisite for establishing effective immunotherapy strategies, there is currently a lack of suitable candidates for the development of such treatments in BC ([@bib23]).

The helicase antigen known as HAGE was first identified in a sarcoma cell line using representational difference analysis ([@bib22]). HAGE was subsequently shown to be expressed in many haematological and solid tumour samples but not in any of the normal tissues tested, except testis ([@bib22]; [@bib3]; [@bib24]) -- it was therefore classified as a Cancer Testes Antigen (CTA). We have previously reported that HAGE protein is required for the proliferation of cancer cells and that it is immunogenic ([@bib3]; [@bib23]).

To date, the clinico-pathological and prognostic significance of HAGE expression in BC remains unknown. We have therefore assessed the clinico-pathological and prognostic and predictive significance of HAGE expression in BC using three well-characterized cohorts of patients (*n*=2147).

Patients and Methods
====================

Study populations
-----------------

Consent was obtained from all the patients as per hospital\'s Standard of Care. This included a clause which permitted the use of excess tissue in research projects that had been approved by both the Local Research Committee and the Hospital Research and Innovations Department.

All work was conducted under the study 'Development of a molecular genetic classification of breast cancer\' and approved by the Nottingham Research Ethics Committee (Ref: C1080301) and the Hospital Research and Innovations Department (Ref: 03HI01).

Early primary BC (EP-BC) cohort
-------------------------------

The study was performed in a 1676 consecutive series of patients with primary invasive BC who were diagnosed between 1986 and 1999 ([@bib9]; [@bib27]). Patients received standard surgery (mastectomy or wide local excision) with radiotherapy. Before 1989, patients did not receive either endocrine or chemotherapy. After 1989, adjuvant-therapy was scheduled on the basis of the Nottingham Prognostic Index (NPI), oestrogen receptor-*α* (ER-*α*) and menopausal status. Patients with NPI scores\<3.4 (low risk) did not receive adjuvant-therapy. Premenopausal patients with NPI scores⩾3.4 (high risk) received cyclophosphamide, Methotrexate and 5-Flourouracil (CMF) combination chemotherapy, and patients with ER-*α*-positive tumours were also offered Tamoxifen for 5 years. The minimum follow-up period was 123 months. Data were randomised into two equal cohorts using a double random number sort. Alternate cases were put into a training set (*n*=838) and a test set (*n*=838). Both cohorts were balanced with regards to HAGE expression, primary clinicopathological features, treatment and survival outcome ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}).

Primary ER-negative BC (PER-BC)
-------------------------------

In order to evaluate the value of HAGE protein expression as a biomarker in the context of current combination cytotoxic chemotherapy, we also analysed its expression in an independent series of 275 patients with PER-BC who had been diagnosed and managed at the same institution between 1999 and 2007, 141 of whom were treated with adjuvant-ACT. Comprehensive follow-up data were available for 275 patients (median=89 months, mean=86 months; [Supplementary Table S2](#sup1){ref-type="supplementary-material"}).

Primary locally advanced BC (PLA-BC)
------------------------------------

Tumour-infiltrating lymphocytes (TILs) and HAGE expression were evaluated in pair-matched prechemotherapy core biopsies and postchemotherapy surgical specimens from 196 female patients with PLA-BC (stage IIIA-C) treated with neoadjuvant-ACT, and their relationship(s) with response to treatment and survival were investigated. These patients were diagnosed by needle core biopsy at the Nottingham University City Hospital between 1996 and 2010. A pathological complete response (pCR) was defined as the absence of any residual invasive carcinoma at both the primary site and in axillary lymph nodes (LNs). On average, 16 breast-blocks and all submitted LNs were examined for each case before a diagnosis of pCR was reached. Detailed patient demographics and clinico-pathological characteristics were routinely assessed and regularly updated ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}).

Pathology assessment of TILs
----------------------------

Histopathological analysis of the TILs was performed on haematoxylin and eosin--stained sections adopting the protocol by [@bib6]). In summary, intratumoral lymphocytes (iTu-Ly) were defined as intraepithelial mononuclear cells within tumour cell nests or in direct contact with tumour cells and were reported as the percentage of the tumour epithelial nests that contain infiltrating lymphocytes. Stromal lymphocytes (str-Ly) were defined as the percentage of tumour stroma area that contains a lymphocytic infiltrate without direct contact to tumour cells. Histopathological analysis was performed by two pathologists (TAF and IOE) who were blinded to clinical and response data; the mean was used for analysis. TILs was classified into three categories: (1) TILs predominant infiltrate defined as the presence of either intratumoral lymphocytes in\>60% of tumour cell nests or lymphocytes in\>60% of the stromal area, (2) focal TILs infiltrate included detectable mononuclear cells\>10% but \<60% of str-Ly or iTu-Ly and (3) no or minimal TILs defined as no detectable or presence of ⩽10% mononuclear cells in tumour cell nests and tumour stroma.

Survival data
-------------

Survival data, including survival time, disease-free survival (DFS) and development of loco-regional and distant metastases (DM), were maintained on a prospective basis. DFS was defined as the number of months from diagnosis to the occurrence of recurrence or DM relapse. BC-specific survival (BCSS) was defined as the number of months from diagnosis to the occurrence of BC-related death. Survival was censored if the patient was still alive, lost to follow-up or died from other causes. The Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) criteria ([@bib25]) were followed throughout this study.

Tissue microarrays (TMAs) and immunohistochemistry (IHC)
--------------------------------------------------------

Tumours from both EP-BC and PER-BC cohorts, as well as postsurgical specimens from patients with PLA-BC, were incorporated into TMAs. These were constructed using six replicate 0.6-mm cores from the centre and periphery of the tumours of each patient. In addition, full-face sections from the diagnostic prechemotherapy core biopsy were used for those PLA-BC cases that were treated with neoadjuvant-ACT. The TMAs and full-face sections were IHC profiled using antibodies for HAGE and other antibodies ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}), as previously described ([@bib1], [@bib2]). IHC staining was performed using a Novolink Detection kit according to the manufacturer\'s protocol (Leica Microsystems, Wetzlar, Germany). For this, sections were incubated overnight at 4 °C with 1/175 dilution of custom-made rabbit anti-HAGE mono-specific polyclonal antibody ([@bib24]). The IHC was validated using a commercially available antibody that was developed and validated as part of the Human Protein Atlas (HPA) project (anti-DDX43; HPA031381, Sigma-Aldrich, St Louis, MO, USA); in this case, sections were incubated overnight at 4 °C at 1/100 dilution ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}).

Expression of HER2, ER and PR was assessed according to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines ([@bib35]; [@bib12]).

To validate the use of TMAs for immuno-phenotyping, full-face sections of 40 cases were stained, and the protein expression levels were compared. The concordance between TMAs and full-face sections was excellent using Cohen\'s *κ*statistical test for categorical variables (*κ*=0.8). Positive and negative (omission of the primary antibody and IgG-matched serum) controls were included in each run.

Evaluation of HAGE immunohistochemical staining
-----------------------------------------------

Tumour cores were evaluated by two pathologists (co-authors: TAF, IOE) who were blinded to the clinico-pathological characteristics of patients in two different settings. Whole-field inspection of the core was scored, and intensities of both nuclear and cytoplasmic staining were grouped as follows: 0=no staining, 1=weak staining, 2=moderate staining, and 3=strong staining. The percentage of each category was estimated and due to intratumoral and intertumoral heterogeneity of the staining, the average percentage among six cores was calculated and high HAGE (HAGE+) expression was defined as the presence of strong cytoplasmic and/or nuclear staining in \>10% of malignant cells ([Figure 1](#fig1){ref-type="fig"}A). Intraobserver (*κ*\>0.8; Cohen\'s *κ* test) and interobserver (*κ*\>0.8; using multi-rater *κ* tests) observer agreements were excellent. In cases where discordant results were obtained, the slides were re-evaluated by both pathologists together, and a consensus was reached.

Statistical analysis
--------------------

Data analysis was performed by (TAF, GRB and SYC) who were blinded to clinical and response data using SPSS (Version 17, Chicago, IL, USA). Where appropriate, Pearson\'s Chi-square and Student\'s tests were used. Positivity for HAGE protein both before and after chemotherapy was calculated and compared using McNemar\'s test. Significance was defined at *P*\<0.05.

Cumulative survival probabilities were estimated using the Kaplan--Meier method, and the differences between survival rates were tested for significance using the log-rank test. Multivariate analysis for survival was performed using the Cox proportional hazard model. The proportional hazards assumption was tested using standard log--log plots. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were estimated for each variable. All tests were two-sided with a 95% CI, and a *P*-value\<0.05 was considered to be indicative of statistical significance. A stringent *P*-value\<0.01 was considered to indicate statistical significance for multiple comparisons.

Results
=======

EP-BC patient group -- training set (*n*=838)
---------------------------------------------

### Clinico-pathological significance of HAGE expression

Eight percent (69 out of 838) of tumours examined were found to be positive for HAGE expression (HAGE+ [Figure 1](#fig1){ref-type="fig"}A). In invasive BC, HAGE+expression was significantly associated with aggressive and adverse pathological features ([Table 1](#tbl1){ref-type="table"}), including high grade, absence of hormonal receptors (ER−/PR−), absence of the anti-apoptotic Bcl2 (Bcl2−), presence of the triple-negative phenotype (TNBC) and overexpression of HER2 (HER2+). Interestingly, none of the invasive lobular carcinomas were HAGE+(0 out of 69).

### HAGE and other biomarkers of cell cycle and mitosis

HAGE+was significantly associated with high mitotic index (MI, *P*=0.002), and high levels of Ki67 (Ki67+ *P*=0.01), KIF2C (KIF2C+ *P*=0.003) and SPAG5 (SPAG5+ *P*=0.01) expression. In the multivariate logistic analysis, high MI (OR (95% CI); 1.5 (1.10--1.98), *P*=0.018) and low Bcl2 expression (OR (95% CI); 0.33 (0.20--0.56), *P*\<0.0001) were independent predictors for HAGE+expression.

### Survival analyses

In the whole cohort (*n*=838), HAGE+expression was associated with adverse clinical outcomes at 10 years, with a significant increase in the risk of death (*P*\<0.0001) ([Figure 1](#fig1){ref-type="fig"}(B-1)) and recurrence (*P*=0.0002) compared with HAGE−tumours. Exploring the clinical outcome of patient subgroups with early-stage tumours ([Figure 1](#fig1){ref-type="fig"}(B-2)), ER+tumours ([Figure 1](#fig1){ref-type="fig"}(B-3)) or patients bearing ER−tumours ([Figure 1](#fig1){ref-type="fig"}(B-4)) confirmed that patients with HAGE+tumours exhibited a worse prognosis than those patients with tumours expressing low levels of HAGE.

### Multivariate Cox regression analysis

HAGE, LN-stage, tumour size and Bcl2 were confirmed as powerful independent predictors for both BCSS and DFS in a multivariate Cox regression model, which included other validated traditional pathological prognostic factors and other co-founders and controlled for endocrine and chemotherapy (*P*\<0.01) ([Table 2](#tbl2){ref-type="table"}).

EP-BC patient group -- test set (*n*=838)
-----------------------------------------

### Clinico-pathological significance of HAGE expression

Eight percent (69 out of 838) of the tumours were HAGE+, and 92% (769 out of 838) tumours were HAGE−. HAGE+expression was significantly associated with high histological grade (*P*=0.0002), ER−/PR−(*P*\<0.001), Bcl2−(*P*\<0.0001), HER2+ (*P*=0.006) and TNBC (*P*=0.0004) ([Table 1](#tbl1){ref-type="table"}). Statistical associations between HAGE+and high p16 (*P*=0.002), high Bax (*P*=0.0004), high EGFR (*P*=0.01) and the presence of basal-like characteristics (*P*=0.004) were observed in the test set but not in the training set, which has been confirmed when the two sets were pooled together. This observation could be due to the borderline imbalance between the test and training sets regarding the expression of EGFR (*P*=050).

### HAGE and other biomarkers of cell cycle and mitosis

HAGE+was significantly associated with high MI (*P*\<0.001), and high expression of Ki67 (*P*=0.027), KIF2C (*P*=0.002) and SPAG5 (*P*=0.004).

### Survival analyses

HAGE+was found to be associated with adverse clinical outcomes in the whole cohort ([Figure 2](#fig2){ref-type="fig"}A; *n*=838), as well as in subgroups that included the LN-negative patients ([Figure 2](#fig2){ref-type="fig"}B), ER+ patients ([Figure 2](#fig2){ref-type="fig"}C) and ER−subpopulations ([Figure 2](#fig2){ref-type="fig"}D) (\<0.01). HAGE, LN stage, tumour size and Bcl2 were independent predictors for BCSS (*P*\<0.01) and DFS (*P*\<0.0001) in multivariate Cox regression analysis ([Table 2](#tbl2){ref-type="table"}).

### HAGE is a prognostic biomarker in low-risk (NPI⩽3.4) BC patients

The expression of HAGE+in low-risk (NPI⩽3.4) BC patients who did not receive either endocrine or chemotherapy was associated with twice the risk of death (HR (95% CI)=1.8 (1.3--2.4), *P*=0.001) and relapse (HR (95% CI)=1.7 (1.3--2.1), *P*=0.000029).

### HAGE is a prognostic biomarker in ER-positive BC patients

In high-risk/ER+BC, HAGE was associated with an adverse outcome at 10 years and an increased risk of death from BC (HR: 1.2; 95% CI: 1.01--1.52; *P*=0.045) and recurrence (HR: 1.4; 95% CI: 1.2--1.7; *P*=0.0001). When high risk/ER+BC patients were stratified according to the status of hormone therapy, HAGE+retained its prognostic effect on DFS in patients who either received (HR: 1.4; 95% CI: 1. 1--1.8; *P*=0.009) or did not receive hormonal therapy (HR: 1.5; 95% CI: 1.2--1.8; *P*=0.001), whereas it lost its prognostic effect on BCSS in patients who did not receive hormonal therapy (HR: 0.96; 95% CI: 0.6--1.4; *P*=0.811).

### HAGE could be a predictor of hormone therapy resistance

ER+/high-risk BC patients who were HAGE−exhibited a prolonged BCSS and DFS when they were exposed to hormone therapy, compared with those who did not receive any hormone therapy (*P*s\<0.0001; [Figure 3](#fig3){ref-type="fig"}A). No benefit was derived from prescribing hormone therapy for ER+/high-risk BC patients with HAGE+([Figure 3](#fig3){ref-type="fig"}B).

### PER-BC patient group

HAGE was highly expressed in 10% (27 out of 275) of the ER-negative cohort of patients with early stage disease ([Figure 4](#fig4){ref-type="fig"}A; *n*=275).

### Relationship between HAGE expression and clinical outcome in patients who received no anthracycline

Similar to our observation in the whole cohort ([Figure 4](#fig4){ref-type="fig"}A), HAGE+expression in patients with high-risk ER−BC who did not receive chemotherapy or received less-effective CMF therapy (*n*=134; [Figure 4](#fig4){ref-type="fig"}B) was associated with adverse clinical outcomes at 5 years, with a significant increase in the risk of death (*P*=0.0005) and recurrence (*P*=0.0003) compared with HAGE−tumours.

### Relationship between HAGE expression and clinical outcome in high risk/ER-negative BC patients who received adjuvant-ACT

Patients whose tumour was found to be HAGE+and received adjuvant-ACT (*n*=141) exhibited a similar risk of death, recurrence and distant metastases to those whose tumour was HAGE−([Figure 4](#fig4){ref-type="fig"}C). This suggests a beneficial effect of ACT.

### PLA-BC patients treated with neo-adjuvant ACT (*n*=196)

To validate the previous observation regarding the effect of HAGE expression and response to ACT, we investigated its expression in PLA-BC patients treated with neoadjuvant-ACT. All patients received neo-adjuvant-ACT, 63% (123 out of 196) without and 37% (73 out of 196) with Taxane ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}). Sixty-three percent of patients received six cycles of FEC (5-fluorouracil 500 mg^−2^, epirubicin 75--100 mg^−2^, cyclophosphamide 500 mg^−2^, on day 1 of a 21-day cycle).

Thirteen percent (26 out of 196) of PLA-BC patients achieved pCR. The rates of pCR were higher for TNBC (26% 14 out of 55) and the ER−/PR−/HER2+subtypes (19% 3 out of 16) than for the ER+/PR+/HER2−(8% 8 out of 104) and ER+/PR+/HER2+ (5% (1 out of 21) subtypes; *P*=0.009).

High prechemotherapy TIL scores were more frequent in the ER−/PR−/HER2+(31% 5 out of 16) and TNBC (27% 15 out of 55) subtypes than in the ER+/PR+/HER2+(19% 4 out of 21) and ER+/PR+/HER2−(11% 11 out of 104) subtypes (*P*=0.029). Postchemotherapy surgical specimens of TNBC subtypes showed higher TIL (31% 17 out of 55) compared with ER−/PR−/HER2+(12.5% 2 out of 16), ER+/PR+/HER2+(9.5% 2 out of 21) and ER+/PR+/HER2−(11.5% 12 out of 104) subtypes (*P*=0.012). A high prechemotherapy TIL score was significantly associated with prechemotherapy HAGE+expression (*P*=0.018).

### Prechemotherapy TILs and HAGE expression are independent predictors of pCR rate for neoadjuvant-ACT

Among the 167 prechemotherapy core biopsies from patients with PLA-BC, 47% (78 out of 167) were HAGE+, and of those 24% (19 out of 78) achieved pCR. Tumours with prechemotherapy TIL+achieved higher pCR rates (40%) compared with those with a TIL− status (7.5%); *P*\<0.0001. Sixty-five percent of prechemotherapy TIL+/HAGE+tumours achieved pCR, and the remaining 35% were HAGE−in postchemotherapy specimens (*P*\<0.0001). In contrast, only 25, 16 and 6% of the prechemotherapy TIL+/HAGE−, TIL−/HAGE+and TIL−/HAGE−tumours achieved pCR, respectively (*P*\<0.0001). Of note was the observation that 51% of prechemotherapy TIL−/HAGE+tumours were found to be HAGE−after receiving neoadjuvant chemotherapy. A statistically significant loss of HAGE expression following neoadjuvant chemotherapy was found among the 106 cases that were paired prechemotherapy and postchemotherapy, (*P*=0.000001; [Supplementary Table 5](#sup1){ref-type="supplementary-material"}).

Multivariate logistic regression analysis showed that prechemotherapy TIL status (OR (95% CI)=5.9 (1.8--20.8), *P*=0.005) and HAGE expression (OR (95% CI)=4.6 (1.3--16.4), *P*=0.021) are independent predictors of pCR in patients with PLA-BC ([Table 3](#tbl3){ref-type="table"}).

### Clinical outcome of HAGE expression and TILs status in PLA-BC

Patients with PLA-BC who received neoadjuvant-ACT and exhibited high levels of HAGE expression before chemotherapy exhibited a risk of progression which was similar to that in PLA-BC patients expressing low/no HAGE (log rank; 1.3, *P*=0.250, [Figure 5](#fig5){ref-type="fig"}(A-1)). However, ER− BC patients who received neoadjuvant ACT and exhibited HAGE+expression before chemotherapy were at a lower risk of progression than in those with HAGE−expression (log rank; 3.89, *P*=.049, [Figure 5](#fig5){ref-type="fig"}(A-2)).

In contrast, patients with HAGE+residual disease after neoadjuvant-ACT exhibited a worse progression-free survival (log rank; 12.8, *P*=0.0003) than those in whom HAGE expression was absent ([Figure 5](#fig5){ref-type="fig"}(B-1)). This was especially the case for patients with ER+tumours (log rank; 7.6, *P*=0.006); [Figure 5(B-2)](#fig5){ref-type="fig"}.

High prechemotherapy TIL status was significantly associated with increased BCSS (HR, 0.07; 95% CI, 0.01 to 0.51; *P*=0.009) and DFS (HR, 0.05; 95% CI, 0.01 to 0.36; *P*=0.003), whereas high postchemotherapy TIL status was associated with increases in DFS (HR, 0.43; 95% CI, 0.19 to 0.94; *P*=0.033) and a trend towards an increased BCSS (HR, 0.41; 95% CI, 0.16 to 1.05; *P*=0.062). The 5-year DFS rates for the high prechemotherapy TILs+/HAGE+ (90%) and TILs+/HAGE− (86%) subgroups were higher than for those with TILs−/HAGE+(53%) and TILs−/HAGE−(46%); *P*=0.001.

Discussion
==========

To the best of our knowledge, this is the first study to report on the prognostic and predictive values of HAGE expression in primary BC. The clinically significant findings of this study are that: (a) HAGE+expression is significantly associated with aggressive clinico-pathological and high proliferation parameters and acts as a novel independent factor for poor prognosis; (b) HAGE+expression identifies a subgroup of PER-BC and PER+BC patients who could benefit from ACT and are resistant to tamoxifen; respectively; and (c) TILs and HAGE+expression in prechemotherapy biopsies are independent predictors of pCR of PLA-BC. Because of the high level of HAGE protein expression in tumours compared with normal tissues, its association with lymphocyte infiltration and the previously reported immunogenic potential of HAGE ([@bib23]), this antigen could be proposed as a novel immunotherapeutic target for this sub-group of BC patients with HAGE+([@bib24]). Work is currently ongoing to confirm that HAGE-specific T cells can indeed kill HAGE-positive BC cells.

In the current study, high levels of HAGE expression was observed in 8--10% of patients with BC and was associated with increased risk of recurrence and metastases. Moreover, an increase in the percentage of HAGE-positive tumours was found between early and locally advanced disease. These findings, along with our previously published data ([@bib20]), support the concept that HAGE is implicated in the progression of the disease by driving cell proliferation and potentially the metastasis of BC cells. HAGE has been shown to be overexpressed at both the mRNA and protein level at varying frequencies in different human tumours ([@bib22]; [@bib3]; [@bib24]) compared with matched normal tissue, with the exception of testes. Furthermore, in agreement with previous studies on other CTA ([@bib19]; [@bib26]; [@bib37]; [@bib21]; [@bib31]; [@bib5]), we have found that HAGE+expression was associated with TNT, less-differentiated, higher-grade tumours and poorer clinical outcome. However, the exact molecular mechanisms underlying the increase of HAGE expression in human cancer remain unclear.

There is substantial evidence that epigenetic events represent one mechanism that regulates the expression of HAGE, and global DNA methylation seems to have a major role ([@bib31]). It has previously been shown that hypomethylation of the HAGE gene promoter correlates with increased HAGE expression and is strongly associated with advanced disease and poor prognosis of leukaemia. This supports the potential role of HAGE in increased cellular proliferation and its potential as a marker of disease progression ([@bib31]). Interestingly, the global hypomethylation of DNA and histones has been shown to progressively increase in parallel with advanced grade and disease progression in human cancers ([@bib18]; [@bib29]; [@bib33]; [@bib28]).

The precise function of HAGE in human cancer remains unknown. We have recently confirmed that HAGE is involved in promoting proliferation via the Ras signalling pathway. This was illustrated by observations that transfection of cells with a HAGE cDNA construct increased cell proliferation of cells and that the silencing of HAGE reduced proliferation ([@bib20]). Moreover, preliminary results using shRNA to permanently knock down HAGE expression also suggest the involvement of HAGE in tumour motility and metastasis (data not shown). [@bib31]) have speculated that HAGE expression might confer a selective advantage over HAGE−cells in blast crisis in leukaemia. Although this would explain the selection of HAGE+cells during the progression of leukaemia, the possible role of HAGE in the transformed status of BC cells needs to be clarified in further functional studies.

In the present study, survival analysis indicates that HAGE is an independent prognostic factor for EP-BC patients. This finding is consistent with the finding in leukaemia, in which HAGE+transcripts have been associated with poor prognosis ([@bib31]; [@bib4]). Similarly, for a given cancer type, higher expression of some other CTAs, such as testes-specific protease 50 (TSP 50) for colorectal ([@bib39]), MAGE-A3 for pancreatic cancer ([@bib17]), MAGE-C2 for hepatocellular carcinoma ([@bib30]) and NY-ESO-1 for malignant melanoma ([@bib34]), were often correlated with poorer outcomes. Recently, [@bib10] found that expression of DEAD-box 1 mRNA is an independent prognostic marker for the early recurrence of BC.

The protein encoded by the HAGE gene is a member of the family of 'DEAD-box proteins\', which function as important transcriptional regulators and are involved in many aspects of RNA metabolism, spermatogenesis, embryogenesis and cell growth ([@bib15]; [@bib38]; [@bib31]). The DEAD-box RNA helicases p68 (DDX5) and p72 (DDX17) have been shown to act as transcriptional co-activators for a diverse range of transcription factors, including oestrogen receptor *α* (ER*α*), and a role for them in miRNA maturation, ribosome biogenesis, mRNA splicing and insulator function have also been described ([@bib32]; [@bib36]). IHC staining of ER*α*-positive primary BC for these DEAD-box proteins indicated that p72 expression was associated with prolonged DFS and OS as well as being inversely associated with HER2 expression. Our studies have found HAGE+expression to be associated with ER-negative expression and other aggressive phenotypes, such as TNBC, HER2 overexpression, proliferation and high grade. Furthermore, HAGE+expression was associated with DFS and BCSS and tamoxifen residence in ER+tumours. However, further functional studies to confirm these preliminary data are warranted.

HAGE expression could prove to be a useful biomarker in the stratification of patients with BC for chemotherapy, as our data show that HAGE+patients may benefit from ACT. It can be postulated that cells expressing HAGE proliferate faster and are therefore more responsive to ACT. A recent study ([@bib39]) has shown that cell proliferation, colony formation, migration and cell apoptosis were reduced/inhibited and cell sensitivity to doxorubicin enhanced, when the TSP50 gene expression was silenced. Moreover, the fact that patients with HAGE+residual disease (ACT-resistant cells) exhibited a poorer outcome suggests that alternative therapy such as immunotherapy may be warranted for this group. [@bib40] have highlighted that anthracyclines, unlike many other cytotoxic agents, can elicit immunogenic cell death and potentiate the potency of vaccines.

The DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine (decitabine) has been shown to be beneficial for patients with chronic myeloid leukaemia ([@bib16]). Drugs that are capable of inducing HAGE expression could therefore increase the eligibility of patients for CTA-targeted immunotherapy and improve the management of patients with recurrent disease.
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![**The clinical outcome of HAGE protein expression in the training set of primary early breast cancer.** (**A**) (1--3) Photomicrographs showing weak nuclear expression of HAGE in normal breast tissue (A-1), breast cancer tissue (A2--3) showing negative expression of HAGE in neoplastic cells (A-2), positive expression of HAGE in neoplastic cells (A-3) (magnification × 200). (**B**) (1--4) Kaplan--Meier curves showing the relationship between HAGE expression and breast cancer-specific and disease-free survival in the training set of primary early breast cancer (PE-BC). See text for details.](bjc2014168f1){#fig1}

![**The clinical outcome of HAGE protein expression in the test set of primary early breast cancer (PE-BC).** Kaplan--Meier curves showing the relationship between HAGE expression and breast cancer-specific survival and disease-free survival in the test set of primary early breast cancer (PE-BC). (**A**) Whole cohort; (**B**) LN− (**C**) ER+ (**D**) high-risk ER− subpopulation. See text for details.](bjc2014168f2){#fig2}

![**The effect of Tamoxifen treatment on the clinical outcome of HAGE protein expression in high risk oestrogen receptor positive (ER+) primary early breast cancer (PE-BC).** (**A**, **B**) Kaplan--Meier curves showing the effect of tamoxifen on breast cancer-specific survival (BCSS) and disease-free survival (DFS) in high-risk primary ER+ breast cancer, stratified according to the HAGE status. (**A**) HAGE negative and (**B**) HAGE positive. See text for details.](bjc2014168f3){#fig3}

![**The clinical outcome of HAGE protein expression in high risk oestrogen receptor negative (ER-) primary early breast cancer (PE-BC).** (**A**--**C**) Kaplan--Meier curves showing the relationship between HAGE expression and breast cancer-specific survival (BCSS) and disease-free survival (DFS) in primary oestrogen receptor-negative breast cancer (PER-BC), stratified according to the received adjuvant chemotherapy protocols. (**A**) Whole cohort, (**B**) no chemotherapy/or less effective CMF and (**C**) anthracycline combination therapy (ACT). See text for details.](bjc2014168f4){#fig4}

![**The clinical outcome of HAGE protein expression in primary locally advanced breast cancer (PLA-BC) before and after receiving neoadjuvant chemotherapy.** (**A**) Kaplan--Meier curves illustrating the relationship between prechemotherapy expression of HAGE and disease-free survival (DFS) in the entire PLA-BC cohort (A-1) and in the ER− subgroup (A-2). (**B**) Kaplan--Meier curves illustrating the relationship between HAGE expression and DFS in patients who exhibited evidence of pathological residual disease after receiving neoadjuvant-ACT in the entire PLA-BC cohort (B-1) and in the ER+ subgroup (B-2).](bjc2014168f5){#fig5}

###### Clinico-pathological characteristics of HAGE protein expression in the discovery and test sets

                                                **Discovery set (*****n*****=838),** ***n*** **(%)**               **Test set (*****n*****=838)**                              
  --------------------------------------------- ------------------------------------------------------ ----------- ---------------------------------- ------------ ----------- ------------------------------------
  **Pathological parameters**                                                                                                                                                  
  Tumour size                                                                                                                                                                  
   T1 a+b (⩽1.0)                                87 (11.4)                                              3 (4.3)                                        90 (11.7)    5 (7.2)      
   T1 c (\>1.0--2.0)                            395 (51.8)                                             38 (55.1)   0.1                                378 (49.3)   37 (53.6)   0.693
   T2 (\>2.0--5.0)                              255 (33.5)                                             28 (40.6)                                      283 (36.9)   26 (37.7)    
   T3 (\>5)                                     25 (3.3)                                               0 (0)                                          15 (2.0)     1 (1.4)      
  **Lymph node stage**                                                                                                                                                         
   Negative                                     484 (63.4)                                             44 (63.8)   0.642                              474 (61.7)   43 (62.3)   0.87
   Positive (1--3 nodes)                        211 (27.7)                                             21 (30.4)                                      228 (29.7)   19 (27.5)    
   Positive (\>3nodes)                          68 (8.9)                                               4 (5.8)                                        66 (8.6)     7 (10.1)     
  **Tumour type**                                                                                                                                                              
   IDC-NST                                      385 (58.6)                                             42 (66.7)                                      367 (55.4)   41 (66.1)    
   Medullary/atypical                           12 (1.8)                                               1 (1.6)     0.052                              19 (2.9)     2 (3.2)     0.074
   Tubular carcinoma                            138 (21.0)                                             14 (22.2)                                      133 (20.1)   14 (22.6)    
   Invasive lobular carcinoma                   81 (12.3)                                              0 (0)                                          73 (11.0)    0 (0)        
   Others                                       41 (6.2)                                               6 (9.5)                                        70 (10.6)    5 (8.1)      
  **Tumour grade**[a](#t1-fn2){ref-type="fn"}                                                                                                                                  
   G1                                           138 (18.1)                                             11 (15.9)   0.001[b](#t1-fn3){ref-type="fn"}   140 (18.3)   5 (7.2)     0.002[b](#t1-fn3){ref-type="fn"}
   G2                                           268 (35.2)                                             11 (15.9)                                      267 (34.9)   17 (24.6)    
   G3                                           356 (46.7)                                             47 (68.1)                                      359 (46.9)   47 (68.1)    
  **Hormonal receptors**                                                                                                                                                       
  **Oestrogen receptor**                                                                                                                                                       
   Negative                                     186 (25.1)                                             28 (40.6)   0.005[b](#t1-fn3){ref-type="fn"}   176 (23.2)   31 (46.3)   0.00003[b](#t1-fn3){ref-type="fn"}
   Positive                                     556 (74.9)                                             41 (59.4)                                      581 (76.8)   36 (53.7)    
  **Progesterone receptor**                                                                                                                                                    
   Negative                                     295 (41.5)                                             39 (56.5)   0.016[b](#t1-fn3){ref-type="fn"}   273 (38.1)   40 (58.8)   0.001[b](#t1-fn3){ref-type="fn"}
   Positive                                     416 (58.5)                                             30 (43.5)                                      444 (61.9)   28 (41.2)    
  **Androgen receptor**                                                                                                                                                        
   Negative                                     210 (35.2)                                             24 (42.1)   0.301                              221 (37.0)   23 (36.5)   0.936
   Positive                                     386 (64.8)                                             33 (57.9)                                      376 (63.0)   40 (63.5)    
  **Proliferation/cell cycle regulators**                                                                                                                                      
  **Mitotic index**                                                                                                                                                            
   M1 (low; mitoses \<10)                       298 (39.4)                                             14 (20.3)   0.002[b](#t1-fn3){ref-type="fn"}   288 (38.0)   10 (14.5)   0.0003[b](#t1-fn3){ref-type="fn"}
   M2 (medium; mitoses 10--18)                  140 (18.5)                                             12 (17.4)                                      142 (18.7)   14 (20.3)    
   M3 (high; mitoses\>18)                       318 (42.1)                                             43 (62.3)                                      328 (43.3)   45 (65.2)    
  **Ki67**                                                                                                                                                                     
   Negative                                     241 (38.7)                                             16 (23.2)   0.011[b](#t1-fn3){ref-type="fn"}   249 (38.7)   17 (25.0)   0.027[b](#t1-fn3){ref-type="fn"}
   Positive                                     382 (61.3)                                             53 (76.8)                                      395 (61.3)   51 (75.0)    
  **KIF2C**                                                                                                                                                                    
   Negative                                     218 (42.7)                                             9 (20.0)    0.003[b](#t1-fn3){ref-type="fn"}   203 (38.7)   9 (17.0)    0.002[b](#t1-fn3){ref-type="fn"}
   Positive                                     292 (57.3)                                             36 (80.0)                                      322 (61.3)   44 (83.0)    
  **SPAG5**                                                                                                                                                                    
   Negative                                     482 (80.7)                                             38 (66.7)   0.012[b](#t1-fn3){ref-type="fn"}   494 (82.9)   37 (66.1)   0.004[b](#t1-fn3){ref-type="fn"}
   Positive                                     115 (19.3)                                             19 (33.3)                                      102 (17.1)   19 (33.9)    
  **TOP2A**                                                                                                                                                                    
   Negative                                     251 (46.2)                                             23 (46.0)   0.976                              254 (47.6)   19 (33.9)   0.066
   Positive                                     292 (53.8)                                             27 (54.0)                                      280 (52.4)   37 (66.1)    
  **P16**                                                                                                                                                                      
   Negative                                     460 (87.1)                                             41 (82.0)   0.308                              455 (87.7)   40 (71.4)   0.002[b](#t1-fn3){ref-type="fn"}
   Positive                                     68 (12.9)                                              9 (18.0)                                       64 (12.3)    16 (28.6)    
  **P53/apoptosis pathways**                                                                                                                                                   
  **P53**                                                                                                                                                                      
   Negative                                     495 (80.9)                                             40 (70.2)   0.053                              484 (79.5)   41 (73.2)   0.175
   Positive                                     117 (19.1)                                             17 (29.8)                                      125 (20.5)   15 (26.8)    
  **Bcl2**                                                                                                                                                                     
   Negative                                     225 (32.9)                                             29 (45.3)   0.045[b](#t1-fn3){ref-type="fn"}   221 (32.2)   38 (58.5)   0.00002[b](#t1-fn3){ref-type="fn"}
   Positive                                     459 (67.1)                                             35 (54.7)                                      466 (67.8)   27 (41.5)    
  **Bax**                                                                                                                                                                      
   Negative                                     309 (69.9)                                             25 (64.1)   0.45                               316 (72.5)   20 (46.5)   0.0004[b](#t1-fn3){ref-type="fn"}
   Positive                                     133 (30.1)                                             14 (35.9)                                      120 (27.5)   23 (53.5)    
  **HER2 Family**                                                                                                                                                              
  **EGFR**                                                                                                                                                                     
   Negative                                     465 (78.7)                                             39 (70.9)   0.183                              486 (83.2)   39 (69.6)   0.011[b](#t1-fn3){ref-type="fn"}
   Overexpression                               126 (21.3)                                             16 (29.1)                                      98 (16.8)    17 (30.4)    
  **HER2**                                                                                                                                                                     
   Negative                                     695 (90.4)                                             56 (81.2)   0.016[b](#t1-fn3){ref-type="fn"}   676 (89.3)   54 (78.3)   0.006[b](#t1-fn3){ref-type="fn"}
   Overexpression                               74 (9.6)                                               13 (18.8)                                      81 (10.7)    15 (21.7)    
  **HER3**                                                                                                                                                                     
   Negative                                     292 (48.4)                                             23 (46.9)   0.841                              321 (52.7)   23 (44.2)   0.251
   Overexpression                               311 (51.6)                                             26 (53.1)                                      288 (47.3)   29 (55.8)    
  **HER4**                                                                                                                                                                     
   Negative                                     270 (43.9)                                             25 (50)     0.404                              255 (42.0)   23 (41.8)   1
   Overexpression                               345 (56.1)                                             25 (50)                                        352 (58.0)   32 (58.0)    
  **Others**                                                                                                                                                                   
  **Triple-negative phenotype**                                                                                                                                                
   No                                           610 (81.7)                                             49 (71)     0.027[b](#t1-fn3){ref-type="fn"}   629 (83.6)   46 (66.7)   0.0004[b](#t1-fn3){ref-type="fn"}
   Yes                                          137 (18.3)                                             20 (29)                                        123 (16.4)   23 (33.3)    
  **Basal-like phenotype**                                                                                                                                                     
   No                                           599 (83.7)                                             51 (79.7)   0.414                              626 (85.6)   46 (72.0)   0.004[b](#t1-fn3){ref-type="fn"}
   Yes                                          117 (16.3)                                             13 (20.3)                                      105 (14.4)   18 (28.0)    

Abbreviations: Basal like=negative expression of both ER and HER2 and either positive expression of EGFR, cytokeratin 14 or cytokeratin 5/6; Bax=BCL2-associated X protein; Bcl2=B-cell CLL/lymphoma 2; EGFR=epidermal growth factor receptor; ER=oestrogen receptor; HAGE=helicase antigen; HER2 (ERBB2)=v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian); HER3 (ERBB3)=v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian), HER4 (ERBB4)=human epidermal receptor 4, IDC-NST=invasive ductal carcinoma -- no special type; KIF2C=kinesin family member 2C; SPAG5=sperm-associated antigen 5, TOP2A=topoisomerase (DNA) II alpha.

Nottingham histological grading system.

Statistically significant.

###### Multivariate Cox regression analysis in the discovery and test sets

                            **BCSS at 10 years**    **DFS at 10 years**                                                                                                                             
  ------------------------- ---------------------- --------------------- ---------------------- ----- ---------- ----------------------- ----- ---------- ------------------------ ----- ---------- ----------------------
  HAGE (high)               2                            1.3--3.1        **0.002\***            1.9    1.3--2.9  **0.002\***             1.7    1.2--2.5  **0.004\***              2.5    1.8--3.5   **1 × 10**^**−7**^\*
  **Lymph node stage**                                                                                                                                                                              
  Negative                  1                                            **0.002\***            1                **6 × 10**^**−10**^\*   1                **1.4 × 10**^**−6**^\*   1                 **7 × 10**^**−6**^\*
  Positive (1--3 nodes)     1.3                          0.9--1.9                               1.7    1.2--2.5                          1.2    0.9--1.6                           1.3    0.9--1.7             
  Positive (\>3 nodes)      2.4                          1.5--3.9                               4.6    2.8--7.2                          2.9    1.9--4.4                           2.7    1.8--4.1             
  **Grade**                                                                                                                                                                                         
  Low (G1)                  1                                            0.754                  1                0.839                   1                0.744                    1                        0.117
  Intermediate (G2)         1.3                          0.6--2.8                               1.1    0.5--2.3                          0.8    0.5--1.3                           1      0.6--1.5             
  High (G3)                 1.5                          0.5--4.1                               0.9    0.3--2.5                          0.9    0.4--1.8                           0.6    0.3--1.2             
  Size (continuous)         1.3                          1.1--1.5        **0.002\***            1      0.9--1.2  0.626                   1.3    1.1--1.4  **4.9 × 10**^**−5**^\*   1      0.9--1.2          0.475
  **Mitotic index**                                                                                                                                                                                 
  M1                        1                                            0.4                    1                0.195                   1                0.362                    1                     **0.030\***
  M2                        1.5                          0.7--2.9                               1.2    0.7--2.4                          1.4    0.9--2.3                           1      0.6--1.6             
  M3                        1.8                          0.8--4.3                               1.9    0.9--4.2                          1.5    0.8--3.0                           1.8    1.0--3.3             
  Ki67 (high)               1.6                          1.0--2.5        0.072                  1.5    1.0--2.4  0.082                   1.1    0.8--1.6  0.508                    1.4    1.0--2.0          0.079
  ER (−)                    2.7                          1.2--5.9        **0.015\***            1.1    0.6--2.4  0.729                   1.5    0.7--3.0  0.288                    1      0.5--1.9          0.993
  HER2 (+)                  1.8                          1.0--3.2        **0.047\***            1.4    0.8--2.5  0.243                   1.2    0.7--2.2  0.473                    1.1    0.6--1.8          0.829
  Bcl2 (−)                  2                            1.4--2.9        **2 × 10**^**−4**^\*   2.6    1.8--3.8  **2 × 10**^**−7**^\*    1.5    1.1--2.0  **0.016\***              2.3    1.7--3.1   **5 × 10**^**−8**^\*
  Triple negative (Yes)     1.4                          0.6--3.3        0.492                  1      0.4--2.4  0.946                   1      0.5--2.2  0.984                    0.7    0.4--1.5          0.734
  Endocrine therapy (Yes)   0.8                          0.6--1.2        0.334                  1      0.7--1.4  0.969                   0.9    0.7--1.2  0.382                    1      0.7--1.3          0.915
  Chemotherapy (Yes)        0.7                          0.5--1.1        0.089                  1      0.6--1.5  0.879                   0.8    0.6--1.1  0.122                    0.9    0.6--1.2          0.479

Abbreviations: Bcl2=B-cell CLL/lymphoma 2; BCSS=breast cancer-specific survival; CI=confidence interval; DFS=disease-free survival; ER=oestrogen receptor; HAGE=helicase antigen; HER2=HER2 (ERBB2)=v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian); HR=hazard ratio.

M1=low; mitoses\<10, M2=medium; mitoses 10--18, M3=high; mitoses\>18. \*Statistically significant (*P*\<0.05).

###### Multivariate regression analysis

  **Factors**                                                    **OR**    **95% CI**   ***P***
  -------------------------------------------------------------- -------- ------------- ----------------------------------
  Tumour-infiltrating lymphocyte(TIL+)                           5.92      1.69--20.78  0.005[a](#t3-fn4){ref-type="fn"}
  Prechemotherapy HAGE (+)                                       4.55      1.26--16.44  0.021[a](#t3-fn4){ref-type="fn"}
  Top2A (+)                                                      4.53      1.10--18.88  0.038[a](#t3-fn4){ref-type="fn"}
  Triple negative (+)                                            3.1       0.84--11.46  0.091
  Clinical TNM stage (II vs III)                                 0.97      0.22--4.25   0.964
  Tumour grade (G1/2 vs G3)\*\*                                  0.4       0.13--1.25   0.114
  Maximum diameter of prechemotherapy tumour size (continuous)   1.01      0.99--1.04   0.422
  Patient age (continuous)                                       1.03      0.96--1.09   0.426

Abbreviations: CI=confidence interval; HAGE=helicase antigen; OR=odds ratio; TNM=Tumour, Node, Metastases; TOP2A=topoisomerase (DNA) II alpha.

TIL, HAGE and TOP2A are independent predictors for pathological complete response.

\*\*Nottingham histological grading system.

Statistically significant.
